Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

The purpose of this project is to develop and evaluate fluorine-18 (F-18) fluorocholine (FCH) positron emission tomography (PET) as an imaging technique that can be used to delineate malignant tumors in the prostate gland. The proposed technique works by measuring the tissue metabolism of FCH, a substrate that is preferentially metabolized by cancer cells due to malignant over-expression of the choline transporter and choline kinase enzyme. The project scope covers a clinical study to recruit men with prostate cancer who have elected treatment by radical prostatectomy surgery. These men will undergo pre-operative PET scanning to measure F-18 FCH uptake in anatomical sextants of the prostate gland. Imaging results will be compared to histopathologic analyses of the prostatectomy specimen to determine the accuracy of F-18 FCH PET for detecting cancerous prostate sextants.

Key facts

Study ID

NCT01310192

Run by

Queen's Medical Center

People needed

20

Starts

2004-06-01

Expected to finish

2008-07-01

Last updated by the study team

2022-07-22

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Clinically Organ Confined Prostate Cancer Electing Radical Prostatectomy

You may not qualify if…

• Weight > 300 lb

Where it is running

• Tripler Army Medical Center — Tripler AMC, Hawaii, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.